Log in

NASDAQ:KROSPassage Bio Stock Price, Forecast & News

-0.42 (-1.48 %)
(As of 05/29/2020 04:00 PM ET)
Today's Range
Now: $28.00
50-Day Range
MA: $27.79
52-Week Range
Now: $28.00
Volume32,100 shs
Average Volume64,657 shs
Market Capitalization$537.29 million
P/E RatioN/A
Dividend YieldN/A
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.40 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:KROS



Sales & Book Value

Annual SalesN/A



Market Cap$537.29 million
Next Earnings Date8/28/2020 (Estimated)
OptionableNot Optionable

Receive KROS News and Ratings via Email

Sign-up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter.

Passage Bio (NASDAQ:KROS) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Passage Bio?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Passage Bio in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Passage Bio.

When is Passage Bio's next earnings date?

Passage Bio is scheduled to release its next quarterly earnings announcement on Friday, August 28th 2020. View our earnings forecast for Passage Bio.

What price target have analysts set for KROS?

4 analysts have issued 12-month price targets for Passage Bio's shares. Their forecasts range from $37.00 to $50.00. On average, they expect Passage Bio's stock price to reach $43.50 in the next year. This suggests a possible upside of 55.4% from the stock's current price. View analysts' price targets for Passage Bio.

Has Passage Bio been receiving favorable news coverage?

News stories about KROS stock have trended neutral this week, according to InfoTrie Sentiment. The research firm scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Passage Bio earned a coverage optimism score of 0.5 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutPassage Bio.

Who are some of Passage Bio's key competitors?

What other stocks do shareholders of Passage Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Passage Bio investors own include AbbVie (ABBV), CVS Health (CVS), Cytokinetics (CYTK), G1 Therapeutics (GTHX), NGM Biopharmaceuticals (NGM), VBI Vaccines (VBIV), Abbott Laboratories (ABT), Akebia Therapeutics (AKBA), Akero Therapeutics (AKRO) and Athenex (ATNX).

Who are Passage Bio's key executives?

Passage Bio's management team includes the following people:
  • Dr. Jasbir Seehra, CEO & Director (Age 64)
  • Mr. Keith C. Regnante, Chief Financial Officer (Age 50)
  • Dr. Jennifer Lachey Ph.D., Chief Scientific Officer (Age 47)
  • Dr. Claudia Ordonez M.D., Chief Medical Officer (Age 54)

When did Passage Bio IPO?

(KROS) raised $75 million in an initial public offering (IPO) on Wednesday, April 8th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, SVB Leerink and Piper Sandler acted as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager.

What is Passage Bio's stock symbol?

Passage Bio trades on the NASDAQ under the ticker symbol "KROS."

When did the company's quiet period expire?

Passage Bio's quiet period expired on Monday, May 18th. Passage Bio had issued 6,000,000 shares in its public offering on April 8th. The total size of the offering was $96,000,000 based on an initial share price of $16.00. During the company's quiet period, insiders and underwriters that worked on the IPO were prevented from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Passage Bio?

Shares of KROS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Passage Bio's stock price today?

One share of KROS stock can currently be purchased for approximately $28.00.

How big of a company is Passage Bio?

Passage Bio has a market capitalization of $537.29 million. Passage Bio employs 23 workers across the globe.

What is Passage Bio's official website?

The official website for Passage Bio is www.kerostx.com.

How can I contact Passage Bio?

Passage Bio's mailing address is 99 HAYDEN AVENUE SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER, LEXINGTON MA, 02421. The company can be reached via phone at 617-314-6297 or via email at [email protected]

This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.